Sanofi’s Supemtek Receives CHMP’s Positive Opinion for Approval to Prevent Influenza

 Sanofi’s Supemtek Receives CHMP’s Positive Opinion for Approval to Prevent Influenza

Sanofi’s Supemtek Receives CHMP’s Positive Opinion for Approval to Prevent Influenza

Shots:

  • The CHMP’s recommendation is based on two P-III studies demonstrating the safety and efficacy of Supemtek (quadrivalent recombinant influenza vaccine) in 10,000+ patients aged ≥18yrs. The company expects EC’s decision in Q4’20
  • Supemtek is the first and only influenza vaccine to rely on recombinant manufacturing technology and is available in the US since 2017
  • Additionally, CHMP also recommends the approval of MenQuadfi for active immunization of individuals aged ≥ 12yrs. against invasive meningococcal ACWY disease with expected EC’s decision by the end of 2020

Source 1, Source 2 ­to­ read full press release/ article | Ref: Sanofi | Image: Campaign Asia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post